Friday, 16 October 2026European Markets

EQVA Stock Was 11.36% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with EQVA (EQVA.OL) jumping 11.36% to kr6.86 on Tuesday, after three sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI slid 2.2% to kr1,397.48, following the last session's downward trend on what was an all-around down trend trading session today.

EQVA's last close was kr6.16, 54% higher than its 52-week high of kr4.00.

About EQVA

Eqva ASA, provides technical solutions and services to maritime and land based industries in Norway and internationally. It operates in three segments: Products, Solutions & Renewables; Real Estate; and Other. The company provides technical installations to the land-based and maritime industry; and develops and operates small-scale hydropower plants. It also engages in real estate business. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was incorporated in 1999 and is headquartered in Kvinnherad, Norway.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr0.26.

PE Ratio

EQVA has a trailing twelve months price to earnings ratio of 26.38. Meaning, the purchaser of the share is investing kr26.38 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.45%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EQVA's stock is considered to be oversold (<=20).

More news about EQVA (EQVA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com